Skip to main content

Anti-obesity drugs


11-06-2017 | Prediabetes | News

Lifestyle interventions have most staying power for diabetes prevention

A meta-analysis shows that although medications and lifestyle changes can both reduce the risk for type 2 diabetes in high-risk patients, only lifestyle modifications have a sustained effect.

05-10-2017 | Liraglutide (T2DM) | News

Liraglutide link with pancreatitis unlikely

Taking the glucagon-like peptide-1 receptor agonist liraglutide does not increase patients’ risk for acute pancreatitis during more than 3 years of treatment, show two reports analyzing the LEADER and SCALE trials.

05-04-2017 | Obesity | News

Assessing diabetes risk could optimize effectiveness of weight loss therapy

Targeting obese patients for weight-loss therapy according to their cardiometabolic status could much improve its effectiveness for diabetes prevention, say researchers.

Read more

Related topics




Journal articles and book chapters

10-13-2017 | Obesity | Review | Article

Current pharmacotherapy for obesity

This review discusses Food and Drug Administration-approved antiobesity drugs in terms of their safety and efficacy in the clinical care of patients with obesity who might not have responded to lifestyle interventions.

Nat Rev Endocrinol 2017. doi:10.1038/nrendo.2017.122

Gitanjali Srivastava, Caroline M. Apovian

08-23-2017 | Obesity | Review | Article

Weight management in patients with type 1 diabetes and obesity

In this review, Mottalib et al. explain the different mechanisms by which patients with type 1 diabetes gain excess body weight and how clinicians can help them manage it.

Mottalib A, Kasetty M, Mar JY, Elseaaidy T, Ashrafzadeh S, Hamdy O. Curr Diab Rep 2017;17:92. doi:10.1007/s11892-017-0918-8

07-31-2017 | Prevention | Review | Article

Pharmaceutical interventions for diabetes prevention in patients at risk

In this review, Chatterjee et al. discuss the various glucose-lowering and other pharmaceutical interventions that have been tested for diabetes prevention and their use in real world settings.

Chatterjee S, Davies M, Khunti K. Am J Cardiovasc Drugs 2017. doi:10.1007/s40256-017-0239-y